单次低剂量靶向贝伐珠单抗输注治疗成人激素难治性脑放射性坏死:一项II期开放标签前瞻性临床试验
这项前瞻性单臂II期试验纳入10例激素难治性、影像学确诊的脑放射性坏死成人患者,在血脑屏障破坏后单次动脉内给予贝伐珠单抗2.5 mg/kg,随访12个月。结果显示3个月时80%患者放射性坏死体积减少>25%,12个月时无复发患者坏死体积中位减少76%、头痛中位减少92%,仅1例(10%)患者仍需激素,2例(20%)出现复发需进一步治疗。
要点
- 血脑屏障破坏后单次动脉内贝伐珠单抗2.5 mg/kg未出现归因于贝伐珠单抗的严重不良事件。
- 3个月时80%患者放射性坏死体积减少>25%,90%患者血管源性水肿体积减少>25%。
- 12个月时8例无复发患者坏死体积中位减少76%、头痛中位减少92%,仅1例(10%)仍需激素。
核心结论
- 作者首次证明单次低剂量靶向贝伐珠单抗输注可使80%患者在治疗后12个月获得持久的临床和影像学改善,且无归因于贝伐珠单抗单独的不良事件。
- 作者认为靶向贝伐珠单抗可能是成人脑放射性坏死的一种高效单次治疗,尚需随机对照试验比较动脉内途径与传统多周期静脉方案。
研究设计与样本
- 前瞻性单臂II期开放标签临床试验,2016年11月至2018年1月纳入10例激素难治性、影像学确诊的脑放射性坏死成人患者,治疗后随访12个月。
- 干预为血脑屏障破坏后立即单次动脉内靶向输注贝伐珠单抗2.5 mg/kg。
- 主要结局为安全性和病灶体积减少>25%,图像由对治疗前诊断和治疗状态设盲的神经放射学专科医师分析。
- 次要结局包括头痛、激素使用、功能状态变化及无神经认知后遗症。
主要发现
- 10例患者平均±标准差年龄35±15岁(范围22-62岁),无患者死亡或出现全身贝伐珠单抗严重不良反应。
- 3个月时80%(95%CI 44%-98%)患者放射性坏死体积减少>25%,90%(95%CI 56%-100%)患者血管源性水肿体积减少>25%。
- 12个月时8例无复发患者放射性坏死体积中位减少76%(范围53%-96%),p=0.012;水肿体积中位减少70%(范围-11%至83%),p=0.086;头痛中位减少92%(范围58%-100%),p=0.022。
- 试验结束时仅1例(10%)患者依赖激素;16项神经认知指标中12项(75%)评分升高。
- 2例(20%)患者在贝伐珠单抗输注后10个月和11个月分别出现放射性坏死复发,需进一步治疗。
关键数值与推荐
- 主要结局指标为病灶体积减少>25%。
- 3个月时放射性坏死体积减少>25%者为80%(95%CI 44%-98%),血管源性水肿体积减少>25%者为90%(95%CI 56%-100%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is an unmet need for safe and rapidly effective therapies for refractory brain radiation necrosis (RN). The aim of this prospective single-arm phase II trial was to evaluate the safety and efficacy of a single low-dose targeted bevacizumab infusion after blood-brain barrier disruption (BBBD) in adult patients with steroid-refractory brain RN. METHODS: Ten adults with steroid-refractory, imaging-confirmed brain RN were enrolled between November 2016 and January 2018 and followed for 12 months after treatment. Bevacizumab 2.5 mg/kg was administered as a one-time targeted intra-arterial infusion immediately after BBBD. Primary outcomes included safety and > 25% decrease in lesion volume. Images were analyzed by a board-certified neuroradiologist blinded to pretrial diagnosis and treatment status. Secondary outcomes included changes in headache, steroid use, and functional status and absence of neurocognitive sequelae. Comparisons were analyzed using the Fisher exact test, Mann-Whitney U-test, linear mixed models, Wilcoxon signed-rank test, and repeated-measures 1-way ANOVA. RESULTS: Ten adults (mean ± SD [range] age 35 ± 15 [22-62] years) participated in this study. No patients died or exhibited serious adverse effects of systemic bevacizumab. At 3 months, 80% (95% CI 44%-98%) and 90% (95% CI 56%-100%) of patients demonstrated > 25% decrease in RN and vasogenic edema volume, respectively. At 12 months, RN volume decreased by 74% (median [range] 76% [53%-96%], p = 0.012), edema volume decreased by 50% (median [range] 70% [-11% to 83%], p = 0.086), and headache decreased by 84% (median [range] 92% [58%-100%], p = 0.022) among the 8 patients without RN recurrence. Only 1 (10%) patient was steroid dependent at the end of the trial. Scores on 12 of 16 (75%) neurocognitive indices increased, thereby supporting a pattern of cerebral white matter recovery. Two (20%) patients exhibited RN recurrence that required further treatment at 10 and 11 months, respectively, after bevacizumab infusion. CONCLUSIONS: For the first time, to the authors' knowledge, the authors demonstrated that a single low-dose targeted bevacizumab infusion resulted in durable clinical and imaging improvements in 80% of patients at 12 months after treatment without adverse events attributed to bevacizumab alone. These findings highlight that targeted bevacizumab may be an efficient one-time treatment for adults with brain RN. Further confirmation with a randomized controlled trial is needed to compare the intra-arterial approach with the conventional multicycle intravenous regimen. Clinical trial registration no.: NCT02819479 (ClinicalTrials.gov).
引用
- Dashti SR, Kadner RJ, Folley BS, et al. Single low-dose targeted bevacizumab infusion in adult patients with steroid-refractory radiation necrosis of the brain: a phase II open-label prospective clinical trial. J Neurosurg. 2022. PMID: 35426830. doi:10.3171/2022.2.JNS212006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。